In terms of tumor subtypes, HR+ /HER2− were 111 (44.4%), HR+ /HER2+ 67 (26.8%), HR−/HER2+ 31 (12.4%) and TN 41 (16.4%), respectively. The gene discussed is ERBB2; the disease is neoplasm.